Perfil microbiológico, prevalencia de resistencia antibiótica y patrones de susceptibilidad en infección urinaria en una población pediátrica


Autoria(s): Suárez Gómez, Diana Maritza; Álvarez, Martha Isabel
Contribuinte(s)

Colmenares Mejía, Claudia Carolina

Data(s)

07/07/2015

31/12/1969

Resumo

Introducción: El incremento de la resistencia antibiótica se considera un problema de salud pública con consecuencias clínicas y económicas, por lo tanto se determinará la prevalencia de resistencia antibiótica en Infección del Tracto Urinario (ITU, el perfil microbiológico y los patrones de susceptibilidad en una población pediátrica atendida en la Fundación Cardioinfantil. Materiales y métodos: Estudio observacional de corte transversal, retrospectivo, entre 1 mes a 18 años de edad, con diagnóstico de ITU comunitaria atendidos entre Enero de 2011 y Diciembre de 2013. Se excluyeron pacientes con dispositivos en la vía urinaria, instrumentación quirúrgica previa, trayectos fistulosos entre la vía urinaria y sistema digestivo, ITU luego de 48 horas de hospitalización y recaída clínica en tratamiento. Se estableció la prevalencia de ITU resistente y se realizó un análisis descriptivo de la información. Resultados: Se evaluaron 385 registros clínicos, con una mediana de 1.08 años (RIQ 0.8 – 4.08), el 73.5% eran niñas. La fiebre predominó (76.5%), seguido de emesis (32.0%), disuria (23.7%) y dolor abdominal (23.1%). El uropatógeno más frecuente fue E.coli (75%), seguido de Proteus mirabilis (8.5%) y Klebsiella spp. (8.3%). La Ampicilina, el Trimetropim sulfametoxazol, la Ampicilina sulbactam y el ácido nalidixico tuvieron mayor tasa de resistencia. La prevalencia de BLEE fue 5.2% y AmpC 3.9%. La prevalencia de resistencia antimicrobiana fue de 11.9%. Conclusiones: La E.coli es el uropatogeno más frecuentemente aislado en ITU, con resistencia a la ampicilina en 60.2%, cefalosporinas de primera generación en 15.5%, trimetropin sulfametoxazol en 43.9%, cefepime 4.8%. La prevalencia de resistencia antimicrobiana fue de 11.9%.

Introduction: The increase of antimicrobial resistance is considered a public health problem with clinic and economic consequences. Therefore, we determine the prevalence of antibiotic resistance in urinary tract infection disease (UTI), th microbiology profile and the patterns of susceptibility in a pediatric population attended in the Fundación Cardioinfantil. Materials and Methods: A retrospective cross-sectional observational study between 1 month and 18 years of age with diagnostic of acquired-community UTI served from January 2011 and December 2013. Patients with UTI after 48 hours of hospitalization, with any dispositive in the urinary way, previous surgery, and presence of fistula between de gastrointestinal tract and the urinary way and the clinic failure in a patient with treatment were excluded. The prevalence of resistance of UTI and a descriptive analysis of the information. Results: 385 clinic records were evaluated, with a median age of 1.08 years (RIQ 0.8 – 4.08), of whom 73.5% are girls. The fever was predominant (76.5%), followed by emesis (32.0%), dysuria (23.7%) and abdominal pain (23.1%). The E.coli was most frequent (75%), followed by Proteus mirabilis(8.5%) and Klebsiella spp(8.3%). Ampicillin, Trimethoprim sulfamethoxazole, sulbactam ampicillin and nalidixic acid have a high rate of resistance. The prevalence of ESBL was of 5.2% and AmpC was 3.9%. The prevalence of global antimicrobial resistance was of 11.9%. Conclusions: The E.coli is the uropathogen most frequent in ITU, with resistance to ampicilin in 60.2%, first generation cephalosporins in 15.5%, trimethroprim sulfamethoxazole in 43.9%, cephepime 4.8%.The prevalence of global antimicrobial resistance was of 11.9%

Formato

application/pdf

Identificador

http://repository.urosario.edu.co/handle/10336/10713

Idioma(s)

spa

Publicador

Facultad de medicina

Direitos

info:eu-repo/semantics/embargoedAccess

Fonte

instname:Universidad del Rosario

reponame:Repositorio Institucional EdocUR

1. Chang SL, Shortliffe LD. Pediatric urinary tract infections. Pediatr Clin North Am. 2006 Jun;53(3):379–400, vi. 2. Prais D, Straussberg R, Avitzur Y, Nussinovitch M, Harel L, Amir J. Bacterial susceptibility to oral antibiotics in community acquired urinary tract infection. Arch Dis Child. 2003 Mar;88(3):215–8. 3. Borsari AG, Bucher B, Brazzola P, Simonetti GD, Dolina M, Bianchetti MG. Susceptibility of Escherichia coli Strains Isolated from Outpatient Children with Community-Acquired Urinary Tract Infection in Southern Switzerland. Clin Ther. 2008;30(11):2090–5. 4. Hoyos A, Serna L, Aterhortúa P, Ortiz G AJ. Infección urinaria de la comunidad en pacientes pediátricos de la Clínica Universitaria Bolivariana. Etiología, presentación clínica, factores de riesgo y respuesta clínica a la terapia empírica inicial. Med UPB. 2010;29(2):89–98. 5. Oteo J, Pérez-Vázquez M, Campos J. Extended-spectrum β-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis. 2010 Aug;23(4):320–6. 6. Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006 Mar 1;42(5):657–68. 7. Livermore DM. Defining an extended-spectrum beta-lactamase. Clin Microbiol Infect. 2008 Jan;14 Suppl 1:3–10. 8. Jadresić L. Urinary tract infections in children. Paediatr Child Health (Oxford). 2014 Jul;24(7):289–92. 9. De la Cruz Paris J, Lozano León JM, Figueroa Serrano JL, Morales Sabogal Y. Manejo de la infección urinaria en niños entre dos meses y cinco años. Guías de pediatría práctica basadas en la evidencia doras. 2004. 191-208 p. 10. Salas P, Barrera P, González C, Zambrano P, Salgado I, Quiroz L, Lillo A, Hevia P CF. Actualización en el diagnóstico y manejo de la Infección Urinaria en pediatría . Rev Child Pediatr. 2012;83(3):269–78. 11. Gastelbondo Amaya R, Lesmes Agudelo A. Infección Urinaria. In: LTDA E medica internacional, editor. El Pediatra Eficiente. Septima Ed. Bogota D.C: Plata Rueda; 2013. p. 717–31. 12. Bours PH a, Polak R, Hoepelman a IM, Delgado E, Jarquin A, Matute a J. Increasing resistance in community-acquired urinary tract infections in Latin America, five years after the implementation of national therapeutic guidelines. Int J Infect Dis. International Society for Infectious Diseases; 2010 Sep;14(9):e770–4. 13. Yumuk Z, Afacan G, Nicolas-Chanoine MH, Sotto A, Lavigne JP. Turkey: A further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15. J Antimicrob Chemother. 2008;62(2):284–8. 14. Andreu A, Planells I. Etiología de la infección urinaria baja adquirida en la comunidad y resistencia de Escherichia coli a los antimicrobianos de primera línea. Estudio nacional multicéntrico. Med Clin (Barc). 2008;130(13):481–6. 15. Bhat RG, Katy T a, Place FC. Pediatric urinary tract infections. Emerg Med Clin North Am. Elsevier Inc; 2011 Aug;29(3):637–53. 16. Castaño, I ., González, C. Biutrago, Z., Rovetto C. Colombia Médica Etiología y sensibilidad bacteriana en infección urinaria en niños . Hospital Infantil Club Noel y Hospital Universitario del Valle , Cali , Colombia Colombia Médica y Consulta Externa del Hospital Universitario del Valle. Colomb Med. 2007;38(Abrril-Junio):100–6. 17. Lozano JM, Domínguez MM, Marrugo T de J. Hallazgos Paraclínicos y Microbiológicos en Infección Urinaria en Pediatría en el Hospital Universitario de San Ignacio. Univ médica. 2000;41(4):194–9. 18. De la Cruz J GG. Infeccion del riñón y de las vias urinarias. Nefrología. Editorial Mosby/Doma, editor. Madrid; 1996. 288-311 p. 19. Evans JHC. Investigation of urinary tract infection in children. Curr Paediatr. 2006 Aug;16(4):248–53. 20. Cullen IM, Manecksha RP, McCullagh E, Ahmad S, O’Kelly F, Flynn R, et al. An 11-year analysis of the prevalent uropathogens and the changing pattern of Escherichia coli antibiotic resistance in 38,530 community urinary tract infections, Dublin 1999-2009. Ir J Med Sci. 2013 Mar;182(1):81–9. 21. Gaspari RJ, Dickson E, Karlowsky J, Doern G. Antibiotic resistance trends in paediatric uropathogens. Int J Antimicrob Agents. 2005 Oct;26(4):267–71. 22. Guidoni EBM, Berezin EN, Nigro S, Santiago N a, Benini V, Toporovski J. Antibiotic resistance patterns of pediatric community-acquired urinary infections. Braz J Infect Dis. 2008 Aug;12(4):321–3. 23. Jackson EC. Urinary Tract Infections in Children : Knowledge Updates and a Salute to the Future. Pediatr Rev. 2015;36(4):153–66. 24. Peirano G, Pitout JDD. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents. 2010 Apr;35(4):316–21. 25. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. EUROSURVEILLANCE. 2008;13(47):1–11. 26. Pitout JDD, Gregson DB, Campbell L, Laupland KB. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob Agents Chemother. 2009 Jul;53(7):2846–51. 27. Peirano G, Richardson D, Nigrin J, McGeer A, Loo V, Toye B, et al. High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada. Antimicrob Agents Chemother. 2010 Mar;54(3):1327–30. 28. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hsueh P-R, Paterson DL. Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrob Agents Chemother. 2009 Aug;53(8):3280–4. 29. Tian G-B, Wang H-N, Zou L-K, Tang J-N, Zhao Y-W, Ye M-Y, et al. Detection of CTX-M-15, CTX-M-22, and SHV-2 extended-spectrum beta-lactamases (ESBLs) in Escherichia coli fecal-sample isolates from pig farms in China. Foodborne Pathog Dis. 2009 Apr;6(3):297–304. 30. Yuan L, Liu J-H, Hu G-Z, Pan Y-S, Liu Z-M, Mo J, et al. Molecular characterization of extended-spectrum beta-lactamase-producing Escherichia coli isolates from chickens in Henan Province, China. J Med Microbiol. 2009 Nov;58(Pt 11):1449–53. 31. Tian SF, Chen BY, Chu YZ, Wang S. Prevalence of rectal carriage of extended-spectrum b-lactamase-producing Escherichia coliamong elderly people incommunity settings in China. Can J Microbiol. 2008;54:781–5. 32. Machado E, Coque TM, Cantón R, Sousa JC, Peixe L. Antibiotic resistance integrons and extended-spectrum {beta}-lactamases among Enterobacteriaceae isolates recovered from chickens and swine in Portugal. J Antimicrob Chemother. 2008 Aug;62(2):296–302. 33. Ben Slama K, Jouini A, Ben Sallem R, Somalo S, Sáenz Y, Estepa V, et al. Prevalence of broad-spectrum cephalosporin-resistant Escherichia coli isolates in food samples in Tunisia, and characterization of integrons and antimicrobial resistance mechanisms implicated. Int J Food Microbiol. Elsevier B.V.; 2010 Feb 28;137(2-3):281–6. 34. Vinué L, Sáenz Y, Martínez S, Somalo S, Moreno M a, Torres C, et al. Prevalence and diversity of extended-spectrum beta-lactamases in faecal Escherichia coli isolates from healthy humans in Spain. Clin Microbiol Infect. 2009 Oct;15(10):954–7. 35. Rodríguez-Baño J, López-Cerero L, Navarro MD, Díaz de Alba P, Pascual A. Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother. 2008 Nov;62(5):1142–9. 36. Guimara B, Radhouani H, Figueiredo N, Gaspar E, Rodrigues J, Torres C, et al. Genetic Detection of Extended-Spectrum Isolates and Vancomycin-Resistant Enterococci in Fecal Samples of Healthy Children. Microb Drug Resist. 2009;15(3):211–7. 37. Yüksel S, Oztürk B, Kavaz A, Ozçakar ZB, Acar B, Güriz H, et al. Antibiotic resistance of urinary tract pathogens and evaluation of empirical treatment in Turkish children with urinary tract infections. Int J Antimicrob Agents. 2006 Nov;28(5):413–6. 38. Cantón R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, et al. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect. 2008 Jan;14 Suppl 1:144–53. 39. Dayan N, Dabbah H, Weissman I, Aga I, Even L, Glikman D. Urinary tract infections caused by community-acquired extended-spectrum β-lactamase-producing and nonproducing bacteria: a comparative study. J Pediatr. Elsevier Ltd; 2013 Nov;163(5):1417–21. 40. Fan N-C, Chen H-H, Chen C-L, Ou L-S, Lin T-Y, Tsai M-H, et al. Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children. J Microbiol Immunol Infect. Elsevier Taiwan LLC; 2013 Jul 5;1–7. 41. Bitsori M, Maraki S, Kalmanti M, Galanakis E. Resistance against broad-spectrum ??-lactams among uropathogens in children. Pediatr Nephrol. 2009;24(12):2381–6. 42. Kuster SP, Hasse B, Huebner V, Bansal V, Zbinden R, Ruef C, et al. Risks factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care university hospital in Switzerland. Infection. 2010 Feb;38(1):33–40. 43. Freeman JT, McBride SJ, Heffernan H, Bathgate T, Pope C, Ellis-Pegler RB. Community-onset genitourinary tract infection due to CTX-M-15-Producing Escherichia coli among travelers to the Indian subcontinent in New Zealand. Clin Infect Dis. 2008 Sep 1;47(5):689–92. 44. Suson KD, Mathews R. Evaluation of children with urinary tract infection--impact of the 2011 AAP guidelines on the diagnosis of vesicoureteral reflux using a historical series. J Pediatr Urol. Elsevier Ltd; 2014 Feb;10(1):182–5. 45. Guideline CP. Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months. Pediatrics. 2011;128(3):595–610. 46. Rodríguez-Baño J, Picón E, Gijón P, Hernández JR, Ruíz M, Peña C, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 2010 Jan 1;50(1):40–8. 47. Biggs WS, Dery WH. Evaluation and treatment of constipation in infants and children. Am Fam Physician. 2006 Feb 1;73(3):469–77.

TEME

Palavras-Chave #Infecciones del tracto urinario en niños #Enterobacterias #Pediatría #618.926 #Farmacorresistencia microbiana #Beta-Lactamasas #Urinary tract infection #Antimicrobial resistance #Pediatrics #Extended spectrum #Blactamase #Enterobacterias #Risk factors
Tipo

info:eu-repo/semantics/bachelorThesis

info:eu-repo/semantics/acceptedVersion